CHS is a condition marked by abdominal pain, nausea, and persistent vomiting linked to prolonged heavy cannabis use. This ...

According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The Food and Drug Administration has approved Nereus (tradipitant) for the prevention of vomiting induced by motion in adults.

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...

While insurance generally covers GLP-1s for the treatment of type 2 diabetes — though sometimes with limitations, depending on the insurance plan — far fewer insurance companies cover the medication ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.